From: Repurposed drugs in combinations exert additive anti-chikungunya virus activity: an in-vitro study
Sr. no. | Drug name | Conc. (µM) | Log diff. | Combination Drugs | Conc. (µM) | Log diff. |
---|---|---|---|---|---|---|
1 | 2-FA | 100 | 1.184 | 2-FA + Emetine 2-FA + Enalprilat 2-FA + Lomibuvir 2-FA + Metyrapone 2-FA + Resveratrol | 100 + 200 100 + 1.56 100 + 6.25 100 + 200 100 + 12.5 | 2.10 2.11 1.00 2.04 1.89 |
2 | Emetine | 200 | 1.215 | Emetine + Enalprilat Emetine + Lomibuvir Ementine + Metyrapone Emetine + Resveratrol | 100 + 1.56 100 + 6.25 100 + 200 100 + 12.5 | 1.14 0.72 1.14 0.24 |
3 | Enalprilat | 100 | 1.08 | Enalprilat + Lomibuvir Enalprilat + Metyrapone Enalprilat + Resveratrol | 1.56 + 6.25 1.56 + 200 1.56 + 100 | 1.19 1.07 0.26 |
4 | Lomibuvir | 6.25 | 1.215 | Lomibuvir + Metyrapone Lomibuvir + Resveratrol | 6.25 + 200 6.25 + 12.5 | 0.93 0.94 |
5 | Metyrapone | 100 | 1.203 | Metyrapone + Resveratrol | 200 + 12.5 | 1.1204 |
6 | Resveratrol | 12.5 | 1.01 | Â | Â | Â |